<SEC-DOCUMENT>0001213900-24-001727.txt : 20240108
<SEC-HEADER>0001213900-24-001727.hdr.sgml : 20240108
<ACCEPTANCE-DATETIME>20240108080202
ACCESSION NUMBER:		0001213900-24-001727
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240108
FILED AS OF DATE:		20240108
DATE AS OF CHANGE:		20240108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		24518411

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea191300-6k_alterity.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-163</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the month of January 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alterity
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm">333-251073</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm">333-248980</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm">333-228671</A>) and our
Registration Statements on Form F-3 (Files No. <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm">333-274816</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm">333-251647</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm">333-231417</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm">333-250076</A>)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALTERITY
THERAPEUTICS LIMITED</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a
development stage enterprise)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are submitted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 9%; font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; font-size: 10pt"><A HREF="ea191300ex99-1_alterity.htm">Alterity Completes Tranche Two of Placement Raising A$3.5M</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Alterity Therapeutics Limited</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Geoffrey P. Kempler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey P. Kempler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: capitalize; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
</FONT>January 8, 2024</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea191300ex99-1_alterity.htm
<DESCRIPTION>ALTERITY COMPLETES TRANCHE TWO OF PLACEMENT RAISING A$3.5M
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Not for release to US wire services
or distribution in the United States</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Alterity Therapeutics Completes
Tranche Two of Placement Raising A$3.5M</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><B>MELBOURNE, AUSTRALIA AND SAN FRANCISCO,
USA &ndash; 8 January 2024:</B> Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (&ldquo;Alterity&rdquo; or &ldquo;the Company&rdquo;),
a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the
Company has completed Tranche Two of a $4.8M (before costs) Placement to Australian and international institutions and other unrelated
sophisticated, professional or other exempt investors first announced on 22 November 2023. This second tranche raised approximately A$3.5M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">As announced on 29 November 2023,
Tranche One of the Placement raised approximately A$1.3M in accordance with the Company&rsquo;s available placement capacity pursuant
to ASX Listing Rules 7.1 (362,462,762 shares). Tranche Two was approved by shareholders at the Extraordinary General Meeting (EGM) on
29 December 2023 and raised approximately A$3.5M (1,008,965,805 shares and all free attaching options). The new shares rank equally with
ATH fully paid ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">As approved by shareholders at the
EGM on 29 December 2023, eligible shareholders with a registered address in Australia and New Zealand at the record date (7.00 pm on 21
November 2023) will be invited to participate in a Securities Purchase Plan (SPP) under which shares and free-attaching options will be
offered on the same terms as the Placement up to a maximum of A$30,000 per eligible shareholder. The maximum total subscription under
the SPP is A$2 million. The SPP offer is only being made to shareholders with a registered address in Australia or New Zealand in the
register of members of the Company, having regard to the compliance costs of making the SPP offer in other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Key Dates for SPP</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border: black 1pt solid; padding-left: 5.5pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>Event</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.75pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Time and Date (AEST)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 0.2pt; padding-right: 5.2pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Record Date for SPP</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.75pt; text-align: right"><FONT STYLE="font-size: 10pt">7:00 pm Tue 21 November</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; text-align: left"><FONT STYLE="font-size: 10pt">SPP Prospectus lodged with ASIC and ASX</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5pt; text-align: right"><FONT STYLE="font-size: 10pt">Fri 29 December</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.2pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Dispatch of the SPP offer booklet</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.95pt; text-align: right"><FONT STYLE="font-size: 10pt">Wed 10 January</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; text-align: left"><FONT STYLE="font-size: 10pt">SPP offer opens</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.95pt; text-align: right"><FONT STYLE="font-size: 10pt">Wed 10 January</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; text-align: left"><FONT STYLE="font-size: 10pt">SPP offer closes</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5pt; text-align: right"><FONT STYLE="font-size: 10pt">5.00 pm, Thu 25 January</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Announcement of results of SPP (including scale back, if any)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.95pt; text-align: right"><FONT STYLE="font-size: 10pt">Fri 2 February</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 0.2pt; padding-left: 5.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Allotment of Shares under the SPP</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.2pt; padding-right: 4.95pt; text-align: right"><FONT STYLE="font-size: 10pt">Fri 2 February</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 0.05pt; padding-left: 5.5pt; text-align: left; width: 70%"><FONT STYLE="font-size: 10pt">Normal trading of SPP shares and dispatch of holding statements</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.05pt; padding-right: 5.1pt; text-align: right; width: 30%"><FONT STYLE="font-size: 10pt">Mon 5 February</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Note: The timetable above is indicative
only and subject to variation. The Company reserves the right to alter the timetable as its absolute discretion and without notice, subject
to the ASX Listing Rules and Corporations Act 2001 (Cth).</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The proceeds from this financing
will provide ongoing funding of Alterity&rsquo;s Phase 2 clinical trials in Multiple System Atrophy (MSA), planning for a potential Phase
3 clinical trial in MSA, continuing discovery and research efforts in neurodegenerative diseases, including Parkinson&rsquo;s Disease,
and general working capital. The placement was managed by MST Financial Pty Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">About Alterity Therapeutics Limited</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Alterity Therapeutics is a clinical
stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company&rsquo;s
lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat
the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For
further information please visit the Company&rsquo;s web site at www.alteritytherapeutics.com.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Authorisation &amp; Additional information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Investor and Media Contacts:</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Australia</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Hannah Howlett</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">we-aualteritytherapeutics@we-worldwide.com</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">+61 450 648 064</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">U.S.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Remy Bernarda</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt">remy.bernarda@iradvisory.com</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">+1 (415) 203-6386</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">Forward Looking Statements</P>

<P STYLE="text-indent: 0pt; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.
The Company has tried to identify such forward-looking statements by use of such words as &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;evidences&rdquo; and &ldquo;estimates,&rdquo; and
other similar expressions, but these words are not the exclusive means of identifying such statements.</I></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>




<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Important factors that could
cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled
&ldquo;Risk Factors&rdquo; in the Company&rsquo;s filings with the SEC, including its most recent Annual Report on Form 20-F as well as
reports on Form 6-K, including, but not limited to the following: statements relating to the Company&rsquo;s drug development program, including,
but not limited to the initiation, progress and outcomes of clinical trials of the Company&rsquo;s drug development program, including, but
not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including,
but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory
approval, production and marketing of the Company&rsquo;s drug components, including, but not limited to, ATH434, the ability of the Company
to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&rsquo;s
drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining
patent protection for the Company&rsquo;s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company&rsquo;s
patent rights and the uncertainty of the Company freedom to operate.</I></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>Any forward-looking statement
made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is
made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V -L# 2(  A$! Q$!_\0
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MM2P<QLL74=",<UM? /Q(8+V^\-7#$"7-Q;ANSCAU_$8/_ 3525X^@%+XR?\
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
